An atypical presentation of immune checkpoint inhibitor associated myositis with normal creatine kinase: a case report
Immune checkpoint inhibitors (ICIs) have been revolutionary in the field of cancer therapeutics. Myositis is a known rheumatic immunotherapy related adverse event with a fatality rate of 26.8% when associated with myasthenia gravis and 51.3% when assoc…